false2021Q1000073176612/31943,702,1200.010.010.013,0003,0003,0009449449469460.0010.0010.0010.001101010——————1.251.08——————4.6254.3753.9504.2504.7004.7502.1254.2004.2503.1503.7503.3754.2502.8754.4502.8753.7003.3502.9002.3753.875—3.1252.7502.8753.5003.5002.3753.7503.7001.2503.1003.4503.3752.9503.8503.8752.8752.0004.6255.8006.5006.6256.8753.5002.7505.7005.9505336400007317662021-01-012021-03-31xbrli:shares00007317662021-04-30iso4217:USD00007317662021-03-3100007317662020-12-31iso4217:USDxbrli:shares00007317662020-01-012020-03-310000731766us-gaap:ProductMember2021-01-012021-03-310000731766us-gaap:ProductMember2020-01-012020-03-310000731766us-gaap:ServiceMember2021-01-012021-03-310000731766us-gaap:ServiceMember2020-01-012020-03-310000731766us-gaap:CommonStockMember2020-12-310000731766us-gaap:AdditionalPaidInCapitalMember2020-12-310000731766us-gaap:RetainedEarningsMember2020-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000731766us-gaap:NoncontrollingInterestMember2020-12-310000731766us-gaap:RetainedEarningsMember2021-01-012021-03-310000731766us-gaap:NoncontrollingInterestMember2021-01-012021-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310000731766us-gaap:CommonStockMember2021-01-012021-03-310000731766us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000731766us-gaap:CommonStockMember2021-03-310000731766us-gaap:AdditionalPaidInCapitalMember2021-03-310000731766us-gaap:RetainedEarningsMember2021-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310000731766us-gaap:NoncontrollingInterestMember2021-03-310000731766us-gaap:CommonStockMember2019-12-310000731766us-gaap:AdditionalPaidInCapitalMember2019-12-310000731766us-gaap:RetainedEarningsMember2019-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000731766us-gaap:NoncontrollingInterestMember2019-12-3100007317662019-12-310000731766us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201613Member2019-12-310000731766us-gaap:AccountingStandardsUpdate201613Member2019-12-310000731766us-gaap:RetainedEarningsMember2020-01-012020-03-310000731766us-gaap:NoncontrollingInterestMember2020-01-012020-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310000731766us-gaap:CommonStockMember2020-01-012020-03-310000731766us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310000731766us-gaap:CommonStockMember2020-03-310000731766us-gaap:AdditionalPaidInCapitalMember2020-03-310000731766us-gaap:RetainedEarningsMember2020-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310000731766us-gaap:NoncontrollingInterestMember2020-03-3100007317662020-03-310000731766us-gaap:USTreasuryAndGovernmentMember2021-03-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2021-03-310000731766us-gaap:CorporateDebtSecuritiesMember2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2021-03-310000731766us-gaap:USTreasuryAndGovernmentMember2020-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000731766us-gaap:CorporateDebtSecuritiesMember2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2020-12-310000731766us-gaap:DebtSecuritiesMember2021-03-310000731766us-gaap:DebtSecuritiesMember2020-12-31xbrli:pure0000731766us-gaap:FairValueInputsLevel1Member2021-03-310000731766us-gaap:FairValueInputsLevel2Member2021-03-310000731766us-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2021-03-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2021-03-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2021-03-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel2Member2021-03-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-03-310000731766us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-03-310000731766us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel1Member2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2021-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2021-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2021-03-310000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:FairValueInputsLevel1Member2020-12-310000731766us-gaap:FairValueInputsLevel2Member2020-12-310000731766us-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2020-12-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2020-12-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel2Member2020-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000731766us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000731766us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2020-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2020-12-310000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2021-03-310000731766us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310000731766us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2021-03-310000731766us-gaap:LongTermDebtMember2021-03-310000731766us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000731766us-gaap:LongTermDebtMember2020-12-310000731766us-gaap:CommercialPaperMember2021-03-310000731766us-gaap:CommercialPaperMember2020-12-310000731766unh:A4.700notesdueFebruary2021Member2021-03-310000731766unh:A4.700notesdueFebruary2021Member2020-12-310000731766unh:A2.125notesdueMarch2021Member2021-03-310000731766unh:A2.125notesdueMarch2021Member2020-12-310000731766unh:FloatingratenotesdueJune2021Member2021-03-310000731766unh:FloatingratenotesdueJune2021Member2020-12-310000731766unh:A3.150notesdueJune2021Member2021-03-310000731766unh:A3.150notesdueJune2021Member2020-12-310000731766unh:A3.375notesdueNovember2021Member2021-03-310000731766unh:A3.375notesdueNovember2021Member2020-12-310000731766unh:A2.875notesdueDecember2021Member2021-03-310000731766unh:A2.875notesdueDecember2021Member2020-12-310000731766unh:A2.875notesdueMarch2022Member2021-03-310000731766unh:A2.875notesdueMarch2022Member2020-12-310000731766unh:A3.350notesdueJuly2022Member2021-03-310000731766unh:A3.350notesdueJuly2022Member2020-12-310000731766unh:A2375NotesDueOctober2022Member2021-03-310000731766unh:A2375NotesDueOctober2022Member2020-12-310000731766unh:ZeroCouponnotesdueNovember2022Member2021-03-310000731766unh:ZeroCouponnotesdueNovember2022Member2020-12-310000731766unh:A2.750notesdueFebruary2023Member2021-03-310000731766unh:A2.750notesdueFebruary2023Member2020-12-310000731766unh:A2.875notesdueMarch2023Member2021-03-310000731766unh:A2.875notesdueMarch2023Member2020-12-310000731766unh:A3.500notesdueJune2023Member2021-03-310000731766unh:A3.500notesdueJune2023Member2020-12-310000731766unh:A3.500notesdueFebruary2024Member2021-03-310000731766unh:A3.500notesdueFebruary2024Member2020-12-310000731766unh:A2.375notesdueAugust2024Member2021-03-310000731766unh:A2.375notesdueAugust2024Member2020-12-310000731766unh:A3.750notesdueJuly2025Member2021-03-310000731766unh:A3.750notesdueJuly2025Member2020-12-310000731766unh:A3.700notesdueDecember2025Member2021-03-310000731766unh:A3.700notesdueDecember2025Member2020-12-310000731766unh:A1250NotesDueJanuary2026Member2021-03-310000731766unh:A1250NotesDueJanuary2026Member2020-12-310000731766unh:A3.100notesdueMarch2026Member2021-03-310000731766unh:A3.100notesdueMarch2026Member2020-12-310000731766unh:A3.450notesdueJanuary2027Member2021-03-310000731766unh:A3.450notesdueJanuary2027Member2020-12-310000731766unh:A3.375notesdueApril2027Member2021-03-310000731766unh:A3.375notesdueApril2027Member2020-12-310000731766unh:A2.950notesdueOctober2027Member2021-03-310000731766unh:A2.950notesdueOctober2027Member2020-12-310000731766unh:A3.850notesdueJune2028Member2021-03-310000731766unh:A3.850notesdueJune2028Member2020-12-310000731766unh:A3.875notesdueDecember2028Member2021-03-310000731766unh:A3.875notesdueDecember2028Member2020-12-310000731766unh:A2.875notesdueAugust2029Member2021-03-310000731766unh:A2.875notesdueAugust2029Member2020-12-310000731766unh:A2000NotesDueMay2030Member2021-03-310000731766unh:A2000NotesDueMay2030Member2020-12-310000731766unh:A4.625notesdueJuly2035Member2021-03-310000731766unh:A4.625notesdueJuly2035Member2020-12-310000731766unh:A5.800notesdueMarch2036Member2021-03-310000731766unh:A5.800notesdueMarch2036Member2020-12-310000731766unh:A6500NotesDueJune2037Member2021-03-310000731766unh:A6500NotesDueJune2037Member2020-12-310000731766unh:A6625NotesDueNovember2037Member2021-03-310000731766unh:A6625NotesDueNovember2037Member2020-12-310000731766unh:A6.875notesdueFebruary2038Member2021-03-310000731766unh:A6.875notesdueFebruary2038Member2020-12-310000731766unh:A3.500notesdueAugust2039Member2021-03-310000731766unh:A3.500notesdueAugust2039Member2020-12-310000731766unh:A2750NotesDueMay2040Member2021-03-310000731766unh:A2750NotesDueMay2040Member2020-12-310000731766unh:A5.700notesdueOctober2040Member2021-03-310000731766unh:A5.700notesdueOctober2040Member2020-12-310000731766unh:A5.950notesdueFebruary2041Member2021-03-310000731766unh:A5.950notesdueFebruary2041Member2020-12-310000731766unh:A4.625notesdueNovember2041Member2021-03-310000731766unh:A4.625notesdueNovember2041Member2020-12-310000731766unh:A4.375notesdueMarch2042Member2021-03-310000731766unh:A4.375notesdueMarch2042Member2020-12-310000731766unh:A3.950notesdueOctober2042Member2021-03-310000731766unh:A3.950notesdueOctober2042Member2020-12-310000731766unh:A4.250notesdueMarch2043Member2021-03-310000731766unh:A4.250notesdueMarch2043Member2020-12-310000731766unh:A4.750notesdueJuly2045Member2021-03-310000731766unh:A4.750notesdueJuly2045Member2020-12-310000731766unh:A4.200notesdueJanuary2047Member2021-03-310000731766unh:A4.200notesdueJanuary2047Member2020-12-310000731766unh:A4.250notesdueApril2047Member2021-03-310000731766unh:A4.250notesdueApril2047Member2020-12-310000731766unh:A3.750notesdueOctober2047Member2021-03-310000731766unh:A3.750notesdueOctober2047Member2020-12-310000731766unh:A4.250notesdueJune2048Member2021-03-310000731766unh:A4.250notesdueJune2048Member2020-12-310000731766unh:A4.450notesdueDecember2048Member2021-03-310000731766unh:A4.450notesdueDecember2048Member2020-12-310000731766unh:A3.700notesdueAugust2049Member2021-03-310000731766unh:A3.700notesdueAugust2049Member2020-12-310000731766unh:A2900NotesDueMay2050Member2021-03-310000731766unh:A2900NotesDueMay2050Member2020-12-310000731766unh:A3.875notesdueAugust2059Member2021-03-310000731766unh:A3.875notesdueAugust2059Member2020-12-310000731766unh:A3125NotesDueMay2060Member2021-03-310000731766unh:A3125NotesDueMay2060Member2020-12-310000731766srt:SubsidiariesMember2021-03-310000731766srt:SubsidiariesMember2020-12-310000731766unh:FiveYear44BillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-03-310000731766unh:ThreeYear44BillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-03-310000731766unh:A364Day38BillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-03-310000731766us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2021-03-310000731766srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2021-03-310000731766unh:FiveYear44BillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-03-310000731766unh:ThreeYear44BillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-03-310000731766unh:A364Day38BillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-03-31unh:reportableSegments0000731766unh:UnitedhealthcareMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptumrxMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberunh:TotalOptumMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310000731766unh:ExternalCustomersMember2021-01-012021-03-310000731766unh:UnitedhealthcareMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:OptumrxMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberunh:TotalOptumMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:ProductMember2021-01-012021-03-310000731766unh:UnitedhealthcareMemberunh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptumrxMemberunh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:IntersegmentEliminationMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:TotalOptumMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMember2021-01-012021-03-310000731766unh:UnitedhealthcareMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptumhealthMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptuminsightMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptumrxMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766us-gaap:IntersegmentEliminationMemberunh:IntersegmentMember2021-01-012021-03-310000731766unh:TotalOptumMemberunh:IntersegmentMember2021-01-012021-03-310000731766us-gaap:CorporateNonSegmentMemberunh:IntersegmentMember2021-01-012021-03-310000731766unh:IntersegmentMember2021-01-012021-03-310000731766unh:UnitedhealthcareMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptumhealthMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptuminsightMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766unh:OptumrxMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310000731766us-gaap:IntersegmentEliminationMember2021-01-012021-03-310000731766unh:TotalOptumMember2021-01-012021-03-310000731766us-gaap:CorporateNonSegmentMember2021-01-012021-03-310000731766unh:UnitedhealthcareMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptumrxMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberunh:TotalOptumMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-310000731766unh:ExternalCustomersMember2020-01-012020-03-310000731766unh:UnitedhealthcareMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:OptumrxMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberunh:TotalOptumMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:ProductMember2020-01-012020-03-310000731766unh:UnitedhealthcareMemberunh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptumrxMemberunh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:IntersegmentEliminationMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:TotalOptumMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-310000731766unh:ExternalCustomersMemberus-gaap:ServiceMember2020-01-012020-03-310000731766unh:UnitedhealthcareMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptumhealthMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptuminsightMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptumrxMemberunh:IntersegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766us-gaap:IntersegmentEliminationMemberunh:IntersegmentMember2020-01-012020-03-310000731766unh:TotalOptumMemberunh:IntersegmentMember2020-01-012020-03-310000731766us-gaap:CorporateNonSegmentMemberunh:IntersegmentMember2020-01-012020-03-310000731766unh:IntersegmentMember2020-01-012020-03-310000731766unh:UnitedhealthcareMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptumhealthMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptuminsightMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766unh:OptumrxMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310000731766us-gaap:IntersegmentEliminationMember2020-01-012020-03-310000731766unh:TotalOptumMember2020-01-012020-03-310000731766us-gaap:CorporateNonSegmentMember2020-01-012020-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________ 
Form 10-Q
__________________________________________________________ 
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED March 31, 2021
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _______ TO _______
Commission File Number: 1-10864
__________________________________________________________ 
UNH-20210331_G1.JPG
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
 __________________________________________________________ 
Delaware   41-1321939
(State or other jurisdiction of
incorporation or organization) 		  (I.R.S. Employer
Identification No.)
UnitedHealth Group Center   55343
9900 Bren Road East
Minnetonka,
Minnesota
(Address of principal executive offices)   (Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
_________________________________________________________  
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $.01 par value UNH New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer ☒ Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐ No ☒
As of April 30, 2021, there were 943,702,120 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.


UNITEDHEALTH GROUP
Table of Contents
 
    Page
1
1
2
3
4
5
6
1.
6
2.
7
3.
9
4.
10
5.
11
6.
12
7.
13
14
22
23
23
23
23
24
25



PART I
ITEM 1.    FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data) March 31,
2021 		December 31,
2020
Assets
Current assets:
Cash and cash equivalents $ 19,955  $ 16,921 
Short-term investments 2,962  2,860 
Accounts receivable, net 15,980  12,870 
Other current receivables, net 11,546  12,534 
Assets under management 4,094  4,076 
Prepaid expenses and other current assets 4,971  4,457 
Total current assets 59,508  53,718 
Long-term investments 42,406  41,242 
Property, equipment and capitalized software, net
8,496  8,626 
Goodwill 72,162  71,337 
Other intangible assets, net 10,842  10,856 
Other assets 11,757  11,510 
Total assets $ 205,171  $ 197,289 
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable $ 24,833  $ 21,872 
Accounts payable and accrued liabilities 22,997  22,495 
Short-term borrowings and current maturities of long-term debt 8,838  4,819 
Unearned revenues 2,612  2,842 
Other current liabilities 21,361  20,392 
Total current liabilities 80,641  72,420 
Long-term debt, less current maturities 37,420  38,648 
Deferred income taxes 3,602  3,367 
Other liabilities 12,926  12,315 
Total liabilities 134,589  126,750 
Commitments and contingencies (Note 6)
Redeemable noncontrolling interests 1,269  2,211 
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding
—  — 
Common stock, $0.01 par value - 3,000 shares authorized; 944 and 946 issued and outstanding
10  10 
Additional paid-in capital —  — 
Retained earnings 71,220  69,295 
Accumulated other comprehensive loss (4,826) (3,814)
Nonredeemable noncontrolling interests
2,909  2,837 
Total equity 69,313  68,328 
Total liabilities, redeemable noncontrolling interests and equity $ 205,171  $ 197,289 
1
UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
  Three Months Ended
March 31,
(in millions, except per share data) 2021 2020
Revenues:
Premiums $ 55,486  $ 50,640 
Products 8,340  8,431 
Services 5,918  4,985 
Investment and other income 452  365 
Total revenues 70,196  64,421 
Operating costs:
Medical costs 44,904  41,000 
Operating costs 10,223  10,015 
Cost of products sold 7,572  7,687 
Depreciation and amortization 758  723 
Total operating costs 63,457  59,425 
Earnings from operations 6,739  4,996 
Interest expense (397) (437)
Earnings before income taxes 6,342  4,559 
Provision for income taxes (1,364) (1,094)
Net earnings 4,978  3,465 
Earnings attributable to noncontrolling interests (116) (83)
Net earnings attributable to UnitedHealth Group common shareholders
$ 4,862  $ 3,382 
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic
$ 5.14  $ 3.56 
Diluted
$ 5.08  $ 3.52 
Basic weighted-average number of common shares outstanding 945  949 
Dilutive effect of common share equivalents 12  13 
Diluted weighted-average number of common shares outstanding
957  962 
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents
3  10 
2
UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
  Three Months Ended
March 31,
(in millions) 2021 2020
Net earnings $ 4,978  $ 3,465 
Other comprehensive loss:
Gross unrealized losses on investment securities during the period (764) (349)
Income tax effect 174  80 
Total unrealized losses, net of tax (590) (269)
Gross reclassification adjustment for net realized gains included in net earnings
(7) (18)
Income tax effect 2  4 
Total reclassification adjustment, net of tax
(5) (14)
Total foreign currency translation losses
(417) (1,499)
Other comprehensive loss (1,012) (1,782)
Comprehensive income 3,966  1,683 
Comprehensive income attributable to noncontrolling interests (116) (83)
Comprehensive income attributable to UnitedHealth Group common shareholders
$ 3,850  $ 1,600 
3
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive
Income (Loss) 		Nonredeemable Noncontrolling Interests Total
Equity
Three months ended March 31,
(in millions) 		Shares Amount Net Unrealized Gains (losses) on Investments Foreign Currency Translation Losses
Balance at January 1, 2021 946  $ 10  $ —  $ 69,295  $ 1,336  $ (5,150) $ 2,837  $ 68,328 
Net earnings
4,862  80  4,942 
Other comprehensive loss (595) (417) (1,012)
Issuances of common stock, and related tax effects
3  —  256  256 
Share-based compensation
242  242 
Common share repurchases (5) —  —  (1,650) (1,650)
Cash dividends paid on common shares ($1.25 per share)
(1,181) (1,181)
Redeemable noncontrolling interests fair value and other adjustments
(498) (106) (604)
Acquisition and other adjustments of nonredeemable noncontrolling interests
66  66 
Distribution to nonredeemable noncontrolling interests
(74) (74)
Balance at March 31, 2021 944  $ 10  $ —  $ 71,220  $ 741  $ (5,567) $ 2,909  $ 69,313 
Balance at January 1, 2020 948  $ 9  $ 7  $ 61,178  $ 589  $ (4,167) $ 2,820  $ 60,436 
Adjustment to adopt ASU 2016-13 (28) (28)
Net earnings
3,382  59  3,441 
Other comprehensive loss (283) (1,499) (1,782)
Issuances of common stock, and related tax effects
5  1  320  321 
Share-based compensation
234  234 
Common share repurchases (6) —  (510) (1,181) (1,691)
Cash dividends paid on common shares ($1.08 per share)
(1,024) (1,024)
Redeemable noncontrolling interests fair value and other adjustments
(51) (51)
Acquisition and other adjustments of nonredeemable noncontrolling interests
50  50 
Distribution to nonredeemable noncontrolling interests
(43) (43)
Balance at March 31, 2020 947  $ 10  $ —  $ 62,327  $ 306  $ (5,666) $ 2,886  $ 59,863 
4
UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
  Three Months Ended March 31,
(in millions) 2021 2020
Operating activities
Net earnings $ 4,978  $ 3,465 
Noncash items:
Depreciation and amortization 758  723 
Deferred income taxes 341  202 
Share-based compensation 256  231 
Other, net (55) 45 
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable (2,895) (2,652)
Other assets (955) (4,249)
Medical costs payable 2,968  1,120 
Accounts payable and other liabilities 870  4,137 
Unearned revenues (261) (79)
Cash flows from operating activities 6,005  2,943 
Investing activities
Purchases of investments (4,612) (3,866)
Sales of investments 643  2,170 
Maturities of investments 2,255  1,726 
Cash paid for acquisitions, net of cash assumed (1,193) (929)
Purchases of property, equipment and capitalized software (568) (469)
Other, net (232) (165)
Cash flows used for investing activities (3,707) (1,533)
Financing activities
Common share repurchases (1,650) (1,691)
Cash dividends paid (1,181) (1,024)
Proceeds from common stock issuances 436  557 
Repayments of long-term debt (1,150) — 
Proceeds from short-term borrowings, net 4,057  10,797 
Customer funds administered 2,131  1,062 
Other, net (1,856) (398)
Cash flows from financing activities 787  9,303 
Effect of exchange rate changes on cash and cash equivalents (51) (129)
Increase in cash and cash equivalents 3,034  10,584 
Cash and cash equivalents, beginning of period 16,921  10,985 
Cash and cash equivalents, end of period $ 19,955  $ 21,569 
5
UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1.    Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health care company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two complementary business platforms — Optum and UnitedHealthcare — are driven by this unified mission and vision to improve health care access, affordability, experiences and outcomes for the individuals and organizations we are privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC (2020 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
6
2.    Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost 		Gross
Unrealized
Gains 		Gross
Unrealized
Losses 		Fair
Value
March 31, 2021
Debt securities - available-for-sale:
U.S. government and agency obligations $ 3,372  $ 86  $ (26) $ 3,432 
State and municipal obligations 6,941  345  (22) 7,264 
Corporate obligations 20,395  533  (122) 20,806 
U.S. agency mortgage-backed securities 6,784  185  (48) 6,921 
Non-U.S. agency mortgage-backed securities 2,382  66  (19) 2,429 
Total debt securities - available-for-sale 39,874  1,215  (237) 40,852 
Debt securities - held-to-maturity:
U.S. government and agency obligations 418  5  —  423 
State and municipal obligations 31  2  —  33 
Corporate obligations 190  —  —  190 
Total debt securities - held-to-maturity 639  7  —  646 
Total debt securities $ 40,513  $ 1,222  $ (237) $ 41,498 
December 31, 2020
Debt securities - available-for-sale:
U.S. government and agency obligations $ 3,335  $ 133  $ (3) $ 3,465 
State and municipal obligations 6,893  435  —  7,328 
Corporate obligations 18,886  863  (12) 19,737 
U.S. agency mortgage-backed securities 6,849  245  (3) 7,091 
Non-U.S. agency mortgage-backed securities 2,116  95  (4) 2,207 
Total debt securities - available-for-sale 38,079  1,771  (22) 39,828 
Debt securities - held-to-maturity:
U.S. government and agency obligations 420  6  —  426 
State and municipal obligations 31  2  —  33 
Corporate obligations 187  1  —  188 
Total debt securities - held-to-maturity 638  9  —  647 
Total debt securities $ 38,717  $ 1,780  $ (22) $ 40,475 
The Company held $2.6 billion and $2.3 billion of equity securities as of March 31, 2021 and December 31, 2020, respectively. The Company’s investments in equity securities primarily consist of employee savings plan related investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $1.3 billion of equity method investments in operating businesses in the health care sector for both March 31, 2021 and December 31, 2020, respectively. The allowance for credit losses on held-to-maturity securities at March 31, 2021 and December 31, 2020 was not material.
7
The amortized cost and fair value of debt securities as of March 31, 2021, by contractual maturity, were as follows:
Available-for-Sale Held-to-Maturity
(in millions) Amortized
Cost 		Fair
Value 		Amortized
Cost 		Fair
Value
Due in one year or less $ 3,037  $ 3,053  $ 354  $ 355 
Due after one year through five years 12,571  12,922  238  242 
Due after five years through ten years 10,945  11,263  25  26 
Due after ten years 4,155  4,264  22  23 
U.S. agency mortgage-backed securities 6,784  6,921  —  — 
Non-U.S. agency mortgage-backed securities 2,382  2,429  —  — 
Total debt securities $ 39,874  $ 40,852  $ 639  $ 646 
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
  Less Than 12 Months 12 Months or Greater  Total
(in millions) Fair
Value 		Gross
Unrealized
Losses 		Fair
Value 		Gross
Unrealized
Losses 		Fair
Value 		Gross
Unrealized
Losses
March 31, 2021
Debt securities - available-for-sale:
U.S. government and agency obligations
$ 924  $ (26) $ —  $ —  $ 924  $ (26)
State and municipal obligations 1,141  (22) 3  —  1,144  (22)
Corporate obligations 5,266  (120) 367  (2) 5,633  (122)
U.S. agency mortgage-backed securities 2,552  (48) 1  —  2,553  (48)
Non-U.S. agency mortgage-backed securities
650  (17) 77  (2) 727  (19)
Total debt securities - available-for-sale $ 10,533  $ (233) $ 448  $ (4) $ 10,981  $ (237)
December 31, 2020
Debt securities - available-for-sale:
U.S. government and agency obligations
$ 346  $ (3) $ —  $ —  $ 346  $ (3)
Corporate obligations 1,273  (9) 456  (3) 1,729  (12)
U.S. agency mortgage-backed securities 601  (3) —  —  601  (3)
Non-U.S. agency mortgage-backed securities
195  (1) 93  (3) 288  (4)
Total debt securities - available-for-sale $ 2,415  $ (16) $ 549  $ (6) $ 2,964  $ (22)
The Company’s unrealized losses from debt securities as of March 31, 2021 were generated from approximately 8,000 positions out of a total of 37,000 positions. The Company believes that it will collect the timely principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since purchase. As of March 31, 2021, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at March 31, 2021 and December 31, 2020 was not material.
8
3.    Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2020 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions) Quoted Prices
in Active
Markets
(Level 1) 		Other
Observable
Inputs
(Level 2) 		Unobservable
Inputs
(Level 3) 		Total
Fair and Carrying
Value
March 31, 2021
Cash and cash equivalents $ 19,880  $ 75  $ —  $ 19,955 
Debt securities - available-for-sale:
U.S. government and agency obligations 3,208  224  —  3,432 
State and municipal obligations —  7,264  —  7,264 
Corporate obligations 29  20,497  280  20,806 
U.S. agency mortgage-backed securities —  6,921  —  6,921 
Non-U.S. agency mortgage-backed securities —  2,429  —  2,429 
Total debt securities - available-for-sale 3,237  37,335  280  40,852 
Equity securities 1,975  27  —  2,002 
Assets under management 1,753  2,286  55  4,094 
Total assets at fair value $ 26,845  $ 39,723  $ 335  $ 66,903 
Percentage of total assets at fair value 40  % 59  % 1  % 100  %
December 31, 2020
Cash and cash equivalents $ 16,841  $ 80  $ —  $ 16,921 
Debt securities - available-for-sale:
U.S. government and agency obligations 3,241  224  —  3,465 
State and municipal obligations —  7,328  —  7,328 
Corporate obligations 25  19,424  288  19,737 
U.S. agency mortgage-backed securities —  7,091  —  7,091 
Non-U.S. agency mortgage-backed securities —  2,207  —  2,207 
Total debt securities - available-for-sale 3,266  36,274  288  39,828 
Equity securities 1,795  33  —  1,828 
Assets under management 1,774  2,250  52  4,076 
Total assets at fair value $ 23,676  $ 38,637  $ 340  $ 62,653 
Percentage of total assets at fair value 38  % 61  % 1  % 100  %
There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2021 or 2020.
9
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions) Quoted Prices
in Active
Markets
(Level 1) 		Other
Observable
Inputs
(Level 2) 		Unobservable
Inputs
(Level 3) 		Total
Fair
Value 		Total Carrying Value
March 31, 2021
Debt securities - held-to-maturity $ 463  $ 110  $ 73  $ 646  $ 639 
Long-term debt and other financing obligations $ —  $ 46,315  $ —  $ 46,315  $ 40,903 
December 31, 2020
Debt securities - held-to-maturity $ 466  $ 108  $ 73  $ 647  $ 638 
Long-term debt and other financing obligations $ —  $ 51,254  $ —  $ 51,254  $ 42,171 
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during either the three months ended March 31, 2021 or 2020.
4.    Medical Costs Payable
The following table shows the components of the change in medical costs payable for the three months ended March 31:
(in millions) 2021 2020
Medical costs payable, beginning of period $ 21,872  $ 21,690 
Acquisitions 12  — 
Reported medical costs:
Current year 45,914  41,580 
Prior years (1,010) (580)
Total reported medical costs 44,904  41,000 
Medical payments:
Payments for current year
(25,960) (23,471)
Payments for prior years (15,995) (16,447)
Total medical payments (41,955) (39,918)
Medical costs payable, end of period $ 24,833  $ 22,772 
For the three months ended March 31, 2021 and March 31, 2020, prior years medical cost reserve development was primarily driven by lower than expected health system utilization. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to the Company of $16.3 billion and $14.8 billion at March 31, 2021 and December 31, 2020, respectively.
10
5.    Short-Term Borrowings and Long-Term Debt
Short-term borrowings and senior unsecured long-term debt consisted of the following:
  March 31, 2021 December 31, 2020
(in millions, except percentages) Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value
Commercial paper $ 5,356  $ 5,355  $ 5,355  $ 1,296  $ 1,296  $ 1,296 
4.700% notes due February 2021
—  —  —  400  400  401 
2.125% notes due March 2021
—  —  —  750  750  753 
Floating rate notes due June 2021
350  350  350  350  350  350 
3.150% notes due June 2021
400  400  402  400  400  405 
3.375% notes due November 2021
500  505  506  500  507  509 
2.875% notes due December 2021
750  759  764  750  762  768 
2.875% notes due March 2022
1,100  1,110  1,120  1,100  1,113  1,127 
3.350% notes due July 2022
1,000  999  1,038  1,000  999  1,048 
2.375% notes due October 2022
900  898  929  900  897  935 
0.000% notes due November 2022
15  14  14  15  14  14 
2.750% notes due February 2023
625  641  648  625  644  654 
2.875% notes due March 2023
750  784  786  750  789  793 
3.500% notes due June 2023
750  748  801  750  748  809 
3.500% notes due February 2024
750  747  813  750  747  821 
2.375% notes due August 2024
750  748  790  750  747  799 
3.750% notes due July 2025
2,000  1,992  2,214  2,000  1,992  2,279 
3.700% notes due December 2025
300  298  333  300  298  344 
1.250% notes due January 2026
500  496  500  500  496  515 
3.100% notes due March 2026
1,000  997  1,086  1,000  997  1,121 
3.450% notes due January 2027
750  747  831  750  747  859 
3.375% notes due April 2027
625  620  686  625  620  714 
2.950% notes due October 2027
950  941  1,024  950  940  1,067 
3.850% notes due June 2028
1,150  1,144  1,290  1,150  1,143  1,367 
3.875% notes due December 2028
850  844  958  850  844  1,019 
2.875% notes due August 2029
1,000  1,015  1,057  1,000  1,086  1,137 
2.000% notes due May 2030
1,250  1,234  1,226  1,250  1,234  1,326 
4.625% notes due July 2035
1,000  992  1,216  1,000  992  1,340 
5.800% notes due March 2036
850  839  1,147  850  839  1,271 
6.500% notes due June 2037
500  492  725  500  492  800 
6.625% notes due November 2037
650  642  959  650  641  1,044 
6.875% notes due February 2038
1,100  1,077  1,648  1,100  1,077  1,802 
3.500% notes due August 2039
1,250  1,242  1,342  1,250  1,241  1,487 
2.750% notes due May 2040
1,000  964  976  1,000  964  1,085 
5.700% notes due October 2040
300  296  412  300  296  451 
5.950% notes due February 2041
350  346  494  350  346  540 
4.625% notes due November 2041
600  589  736  600  589  820 
4.375% notes due March 2042
502  485  593  502  485  661 
3.950% notes due October 2042
625  608  712  625  608  790 
4.250% notes due March 2043
750  735  878  750  735  982 
4.750% notes due July 2045
2,000  1,974  2,496  2,000  1,974  2,814 
4.200% notes due January 2047
750  738  875  750  738  991 
4.250% notes due April 2047
725  718  847  725  717  963 
3.750% notes due October 2047
950  934  1,031  950  934  1,180 
4.250% notes due June 2048
1,350  1,330  1,592  1,350  1,330  1,803 
4.450% notes due December 2048
1,100  1,087  1,345  1,100  1,086  1,517 
3.700% notes due August 2049
1,250  1,235  1,354  1,250  1,235  1,567 
2.900% notes due May 2050
1,250  1,208  1,193  1,250  1,208  1,384 
3.875% notes due August 2059
1,250  1,228  1,391  1,250  1,228  1,618 
3.125% notes due May 2060
1,000  963  979  1,000  965  1,161 
Total short-term borrowings and long-term debt $ 45,473  $ 45,108  $ 50,462  $ 42,563  $ 42,280  $ 51,301 
11
The Company’s long-term debt obligations also included $1.2 billion of other financing obligations as of both March 31, 2021 and December 31, 2020, of which $359 million and $354 million were classified as current as of March 31, 2021 and December 31, 2020, respectively.
Short-Term Borrowings
Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of March 31, 2021, the Company’s outstanding commercial paper had a weighted average annual interest rate of 0.2%.
The Company has $4.4 billion five-year, $4.4 billion three-year and $3.8 billion 364-day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. As of March 31, 2021, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of March 31, 2021, annual interest rates would have ranged from 0.8% to 0.9%.
Debt Covenants
The Company’s bank credit facilities contain various covenants, including covenants requiring the Company to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. The Company was in compliance with its debt covenants as of March 31, 2021.
6.    Commitments and Contingencies
Pending Acquisitions
The Company has entered into agreements to purchase companies in the health care sector, most notably Change Healthcare (NASDAQ: CHNG), which is expected to close in the second half of 2021, subject to regulatory approvals and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $12 billion.
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
12
On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.
7.    Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more information on the Company’s segments see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2020 10-K.
The following tables present reportable segment financial information:
    Optum    
(in millions) UnitedHealthcare OptumHealth OptumInsight OptumRx Optum Eliminations Optum Corporate and
Eliminations 		Consolidated
Three Months Ended March 31, 2021
Revenues - unaffiliated customers:
Premiums $ 52,558  $ 2,928  $ —  $ —  $ —  $ 2,928  $ —  $ 55,486 
Products —  8  37  8,295  —  8,340  —  8,340 
Services 2,350  2,336  961  271  —  3,568  —  5,918 
Total revenues - unaffiliated customers
54,908  5,272  998  8,566  —  14,836  —  69,744 
Total revenues - affiliated customers
—  6,952  1,821  13,004  (475) 21,302  (21,302) — 
Investment and other income
206  179  33  34  —  246  —  452 
Total revenues $ 55,114  $ 12,403  $ 2,852  $ 21,604  $ (475) $ 36,384  $ (21,302) $ 70,196 
Earnings from operations $ 4,108  $ 962  $ 779  $ 890  $ —  $ 2,631  $ —  $ 6,739 
Interest expense —  —  —  —  —  —  (397) (397)
Earnings before income taxes
$ 4,108  $ 962  $ 779  $ 890  $ —  $ 2,631  $ (397) $ 6,342 
Three Months Ended March 31, 2020
Revenues - unaffiliated customers:
Premiums $ 48,593  $ 2,047  $ —  $ —  $ —  $ 2,047  $ —  $ 50,640 
Products —  9  29  8,393  —  8,431  —  8,431 
Services 2,278  1,548  891  268  —  2,707  —  4,985 
Total revenues - unaffiliated customers
50,871  3,604  920  8,661  —  13,185  —  64,056 
Total revenues - affiliated customers
—  5,452  1,562  12,876  (404) 19,486  (19,486) — 
Investment and other income
197  136  12  20  —  168  —  365 
Total revenues $ 51,068  $ 9,192  $ 2,494  $ 21,557  $ (404) $ 32,839  $ (19,486) $ 64,421 
Earnings from operations $ 2,888  $ 712  $ 536  $ 860  $ —  $ 2,108  $ —  $ 4,996 
Interest expense —  —  —  —  —  —  (437) (437)
Earnings before income taxes
$ 2,888  $ 712  $ 536  $ 860  $ —  $ 2,108  $ (437) $ 4,559 

13
ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2020 10-K, including the Consolidated Financial Statements and Notes in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2020 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health care company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two complementary businesses — Optum and UnitedHealthcare — are driven by this unified mission and vision to improve health care access, affordability, experiences and outcomes for the individuals and organizations we are privileged to serve.
We have four reportable segments across our two business platforms, Optum and UnitedHealthcare:
•OptumHealth;
•OptumInsight;
•OptumRx; and
•UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State and UnitedHealthcare Global.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 10-K and additional information on our segments can be found in this Item 2 and in Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic continues to evolve and the ultimate impact on our business, results of operations, financial condition and cash flows remains uncertain. During the three months ended March 31, 2021, overall care activity, including COVID-19 related care, was nearly at seasonal baselines. This was primarily the result of temporary deferral of elective care activity, which generally tracked with COVID-19 incidence rates during the quarter. For the three months ended March 31, 2021, the temporary deferral of care was more than offset by COVID-19 related care and testing costs, rebate requirements, and general economic impacts, such as impacts of unemployment. The temporary deferral of care, along with continued COVID-19 related care costs, may cause care patterns to moderately exceed normal baselines in future periods as utilization of health system capacity increases and consumers resume elective care. From time to time, health system capacity may be subject to possible increased volatility due to the pandemic. Specific trends and uncertainties related to our two business platforms are as follows:
Optum. COVID-19 related care costs continued to impact our OptumHealth risk-based care delivery businesses, which were partially offset by the continued temporary deferral of care. The temporary deferral of care reduced fee-for-service care delivery volume, as well as OptumInsight and OptumRx volume-based business activity. We believe COVID-19 will continue to influence customer and consumer behavior, both during and after the pandemic, which could impact how care is delivered and the manner in which consumers wish to receive their prescription drugs or infusion services. We expect COVID-19 related care costs and other economic impacts to only partially be offset by temporary deferrals of care in the second half of the year as health systems return to seasonally adjusted levels of care. As a result of the dynamic situation and broad-reaching impact to the health system, the ultimate impact of COVID-19 on our Optum businesses is uncertain.
14
UnitedHealthcare. In 2021, we have continued expanded benefit coverage in areas such as COVID-19 related care and testing, telemedicine, and pharmacy; continuing to assist our customers, care providers, members and communities in addressing the COVID-19 crisis. Temporary care deferrals continued to impact UnitedHealthcare’s results of operations for the three months ended March 31, 2021, offset by COVID-19 related care and testing, rebate requirements and other revenue impacts and broader economic impacts. Enrollment in our commercial products declined primarily due to employer actions in response to the pandemic.
Increased consumer demand for care, potentially even higher acuity care, along with continued COVID-19 related care and testing costs are expected to result in increased future medical costs in the second half of the year. Disrupted care patterns, as a result of the pandemic, have and may continue to temporarily affect the ability to obtain complete member health status information, impacting revenue in businesses utilizing risk adjustment methodologies. The ultimate overall impact is uncertain and dependent on the future pacing and intensity of the pandemic, the duration of policies and initiatives to address COVID-19, and general economic uncertainty.
Business Trends
Our businesses participate in the United States, South American and certain other international health markets. Overall spending on health care is impacted by inflation; utilization; medical technology and pharmaceutical advancement; regulatory requirements; demographic trends in the population; and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macro-economic conditions, such as the impacts of COVID-19, and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs, including any potential impacts from COVID-19. We frequently evaluate and adjust our approach in each of the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio (MLR) thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in both the small group and large group segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs amid reform changes.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization and prescription drug costs. COVID-19 related care and testing costs as well as the deferral of care have also impacted medical cost trends in the current year and may continue in future years. We endeavor to mitigate those increases by engaging physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high quality, affordable care. The continued uncertain impact of COVID-19 may impact our ability to estimate medical costs payable, which has resulted in, and could result in, increased variability to medical cost reserve development.
Regulatory Trends and Uncertainties
Following is a summary of management’s view of regulatory trends and uncertainties. For additional information regarding regulatory trends and uncertainties, see Part I, Item 1 “Business - Government Regulation,” Part 1, Item 1A, “Risk Factors,” Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 10-K and “Risk Factors” in Part II, Item 1A of this report.
Medicare Advantage Rates. Final 2022 Medicare Advantage rates resulted in an increase in industry base rates of approximately 4.1%, short of the industry forward medical cost trend. We continue to manage costs through improving and expanding our coordinated care models, value-based care arrangements and various consumer engagement tools.
Affordable Care Act (ACA) Tax. The Health Insurance Tax was permanently repealed by Congress, effective January 1, 2021. The permanent repeal of the tax impacts year-over-year comparability of our financial statements, including revenues, operating costs, medical care ratio (MCR), operating cost ratio, effective tax rate and cash flows from operations.
15
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select first quarter 2021 year-over-year operating comparisons to first quarter 2020.
•Consolidated revenues grew 9%, UnitedHealthcare revenues grew 8% and Optum revenues grew 11%.
•UnitedHealthcare served 1.1 million more people domestically, driven by growth in community and senior programs, partially offset by decreased people served by our commercial benefits business.
•Consolidated earnings from operations increased 35%, including increases of 42% at UnitedHealthcare and 25% at Optum.
•Diluted earnings per common share increased 44% to $5.08.
•Cash flows from operations for the three months ended March 31, 2021 were $6.0 billion.
•Return on equity was 29.5%.
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data) Three Months Ended March 31, Increase/(Decrease)
2021 2020 2021 vs. 2020
Revenues:
Premiums $ 55,486  $ 50,640  $ 4,846  10  %
Products 8,340  8,431  (91) (1)
Services 5,918  4,985  933  19 
Investment and other income
452  365  87  24 
Total revenues 70,196  64,421  5,775  9 
Operating costs:
Medical costs 44,904  41,000  3,904  10 
Operating costs 10,223  10,015  208  2 
Cost of products sold 7,572  7,687  (115) (1)
Depreciation and amortization
758  723  35  5 
Total operating costs 63,457  59,425  4,032  7 
Earnings from operations 6,739  4,996  1,743  35 
Interest expense (397) (437) 40  (9)
Earnings before income taxes 6,342  4,559  1,783  39 
Provision for income taxes (1,364) (1,094) (270) 25 
Net earnings 4,978  3,465  1,513  44 
Earnings attributable to noncontrolling interests
(116) (83) (33) 40 
Net earnings attributable to UnitedHealth Group common shareholders
$ 4,862  $ 3,382  $ 1,480  44  %
Diluted earnings per share attributable to UnitedHealth Group common shareholders
$ 5.08  $ 3.52  $ 1.56  44  %
Medical care ratio (a) 80.9  % 81.0  % (0.1) %
Operating cost ratio 14.6  15.5  (0.9)
Operating margin 9.6  7.8  1.8 
Tax rate 21.5  24.0  (2.5)
Net earnings margin (b) 6.9  5.2  1.7 
Return on equity (c) 29.5  % 23.6  % 5.9  %
(a)Medical care ratio is calculated as medical costs divided by premium revenue.
(b)Net earnings margin attributable to UnitedHealth Group shareholders.
(c)Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the quarters in the year presented.
16
2021 RESULTS OF OPERATIONS COMPARED TO 2020 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenue
The increases in revenue were primarily driven by the increase in the number of individuals served through Medicare Advantage and Medicaid; pricing trends; and organic and acquisition growth across the Optum business, primarily due to expansion in care delivery and managed services. The increases were partially offset by decreased individuals served through our commercial benefits business due to the continued economic impacts of COVID-19.
Medical Costs and MCR
Medical costs increased as a result of growth in people served through Medicare Advantage and Medicaid, medical cost trends and COVID-19 related care and testing costs, partially offset by the temporary deferral of care continued to be caused by COVID-19, decreased people served in commercial, increased prior year favorable reserve development and calendar day impacts. The MCR was stable due to the temporary deferral of care, increased prior year favorable reserve development and calendar day impacts, being offset by the permanent repeal of the Health Insurance Tax and COVID-19 related care and testing costs.
Operating Cost Ratio
The operating cost ratio decreased primarily due to the permanent repeal of the return of the Health Insurance Tax and operating efficiency gains, partially offset by business mix.
Income Tax Rate
Our effective tax rate decreased primarily due to the permanent repeal of the nondeductible Health Insurance Tax.
Reportable Segments
See Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including individuals served by UnitedHealthcare by major market segment and funding arrangement, people served by OptumHealth and adjusted scripts for OptumRx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, customer penetration and pricing trends when comparing the metrics to revenue by segment.
17
The following table presents a summary of the reportable segment financial information:
  Three Months Ended March 31, Increase/(Decrease)
(in millions, except percentages) 2021 2020 2021 vs. 2020
Revenues
UnitedHealthcare $ 55,114  $ 51,068  $ 4,046  8  %
OptumHealth 12,403  9,192  3,211  35 
OptumInsight 2,852  2,494  358  14 
OptumRx 21,604  21,557  47  — 
Optum eliminations (475) (404) (71) 18 
Optum
36,384  32,839  3,545  11 
Eliminations (21,302) (19,486) (1,816) 9 
Consolidated revenues $ 70,196  $ 64,421  $ 5,775  9  %
Earnings from operations
UnitedHealthcare $ 4,108  $ 2,888  $ 1,220  42  %
OptumHealth 962  712  250  35 
OptumInsight 779  536  243  45 
OptumRx 890  860  30  3 
Optum
2,631  2,108  523  25 
Consolidated earnings from operations
$ 6,739  $ 4,996  $ 1,743  35  %
Operating margin
UnitedHealthcare 7.5  % 5.7  % 1.8  %
OptumHealth 7.8  7.7  0.1 
OptumInsight 27.3  21.5  5.8 
OptumRx 4.1  4.0  0.1 
Optum
7.2  6.4  0.8 
Consolidated operating margin 9.6  % 7.8  % 1.8  %
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
  Three Months Ended March 31, Increase/(Decrease)
(in millions, except percentages) 2021 2020 2021 vs. 2020
UnitedHealthcare Employer & Individual
$ 14,632  $ 14,280  $ 352  2  %
UnitedHealthcare Medicare & Retirement
25,474  23,152  2,322  10 
UnitedHealthcare Community & State
12,973  11,453  1,520  13 
UnitedHealthcare Global 2,035  2,183  (148) (7)
Total UnitedHealthcare revenues $ 55,114  $ 51,068  $ 4,046  8  %
18
The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
March 31, Increase/(Decrease)
(in thousands, except percentages) 2021 2020 2021 vs. 2020
Commercial:
Risk-based 7,860  8,215  (355) (4) %
Fee-based 18,455  18,825  (370) (2)
Total commercial 26,315  27,040  (725) (3)
Medicare Advantage 6,335  5,575  760  14 
Medicaid 6,975  5,880  1,095  19 
Medicare Supplement (Standardized) 4,390  4,440  (50) (1)
Total community and senior 17,700  15,895  1,805  11 
Total UnitedHealthcare - domestic medical 44,015  42,935  1,080  3 
Global 5,460  5,605  (145) (3)
Total UnitedHealthcare - medical 49,475  48,540  935  2  %
Supplemental Data:
Medicare Part D stand-alone 3,795  4,150  (355) (9) %
Fee-based and risk-based commercial business decreased primarily due to increased unemployment. Medicare Advantage increased due to growth in people served through individual and group Medicare Advantage plans. The increase in people served through Medicaid was primarily driven by states continuing to ease redetermination requirements due to COVID-19, new state-based awards and growth in people served through Dual Special Needs Plans.
UnitedHealthcare’s revenue increased due to growth in the number of individuals served through Medicare Advantage and Medicaid and a greater mix of people with higher acuity needs, partially offset by a decrease in the number of individuals served through commercial benefits and the permanent repeal of the Health Insurance Tax. Earnings from operations increased due to the continued deferral of care caused by COVID-19 on the health system, the growth in people served through Medicare Advantage and Medicaid and the repeal of the Health Insurance Tax, partially offset by COVID-19 related care and testing costs, the reduction in people served through commercial benefits and broader economic impacts of COVID-19.
Optum
Total revenues and earnings from operations increased due to growth at OptumHealth and OptumInsight. The results by segment were as follows:
OptumHealth
Revenue and earnings from operations at OptumHealth increased primarily due to organic growth and acquisitions in care delivery. Earnings from operations were also impacted by the temporary deferral of care at our risk-based businesses caused by COVID-19 and cost management initiatives, partially offset by COVID-19 related care costs. OptumHealth served approximately 99 million people as of March 31, 2021 compared to 96 million people as of March 31, 2020.
OptumInsight
Revenue at OptumInsight increased primarily due to growth in technology and managed services, partially offset by decreased activity levels in volume-based services due to the impact of COVID-19 on payer and care provider clients. Earnings from operations increased primarily due to productivity gains and cost management initiatives, as well as the factors impacting revenue.
OptumRx
Revenue and earnings from operations at OptumRx grew modestly due to organic growth and acquisitions in pharmacy care services and pricing trends, offset by lower script volumes. OptumRx fulfilled 329 million and 339 million adjusted scripts in the first quarters of 2021 and 2020, respectively, as the first quarter 2020 included the advance provision of medications to people served in response to COVID-related supply concerns, with script levels then receding with care deferral patterns.
19
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
  Three Months Ended March 31, Increase/(Decrease)
(in millions) 2021 2020 2021 vs. 2020
Sources of cash:
Cash provided by operating activities $ 6,005  $ 2,943  $ 3,062 
Issuances of short-term borrowings and long-term debt, net of repayments
2,907  10,797  (7,890)
Proceeds from common stock issuances 436  557  (121)
Customer funds administered
2,131  1,062  1,069 
Sales and maturities of investments, net of purchases —  30  (30)
Total sources of cash 11,479  15,389 
Uses of cash:
Common stock repurchases (1,650) (1,691) 41 
Cash paid for acquisitions, net of cash assumed
(1,193) (929) (264)
Purchases of investments, net of sales and maturities (1,714) —  (1,714)
Purchases of property, equipment and capitalized software
(568) (469) (99)
Cash dividends paid
(1,181) (1,024) (157)
Other (2,088) (563) (1,525)
Total uses of cash (8,394) (4,676)
Effect of exchange rate changes on cash and cash equivalents
(51) (129) 78 
Net increase in cash and cash equivalents $ 3,034  $ 10,584  $ (7,550)
2021 Cash Flows Compared to 2020 Cash Flows
Increased cash flows provided by operating activities were primarily driven by increased net earnings and changes in working capital accounts. Other significant changes in sources or uses of cash year-over-year included decreased short-term borrowings and increased purchases of investments, partially offset by increased customer funds administered.
Financial Condition
As of March 31, 2021, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $63.4 billion included approximately $20.0 billion of cash and cash equivalents (of which $2.1 billion was available for general corporate use), $40.9 billion of debt securities and $2.6 billion of investments in equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration of 3.8 years and a weighted-average credit rating of “Double A” as of March 31, 2021. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2020 was disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations ” in our 2020 10-K. During the three months ended March 31, 2021, there were no material changes to this previously disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and acquisitions.

20
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of March 31, 2021, our debt to debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 39%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Credit Ratings. Our credit ratings as of March 31, 2021 were as follows:
  
Moody’s S&P Global Fitch A.M. Best
  Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook
Senior unsecured debt
A3 Stable A+ Stable A Stable A- Positive
Commercial paper P-2 n/a A-1 n/a F1 n/a AMB-1 n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the three months ended March 31, 2021, we repurchased approximately 5 million shares at an average price of $345.42 per share. As of March 31, 2021, we had Board authorization to purchase up to 53 million shares of our common stock.
Dividends. Our quarterly cash dividend to shareholders reflects an annual dividend rate of $5.00 per share.
Pending Acquisitions. The Company has entered into agreements to purchase companies in the health care sector, most notably Change Healthcare (NASDAQ: CHNG), which is expected to close in the second half of 2021, subject to regulatory approvals and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $12 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 in our 2020 10-K.
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 in our 2020 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in our 2020 10-K.

21
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; risks and uncertainties associated with the pharmacy benefits management industry; competitive pressures; changes in or challenges to our public sector contract awards; our ability to contract on competitive terms with physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S. income tax rate applicable to corporations); failure to achieve targeted operating cost productivity improvements; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March 31, 2021 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
March 31, 2021
Increase (Decrease) in Market Interest Rate Investment
Income Per
Annum (a) 		Interest
Expense Per
Annum (a) 		Fair Value of
Financial Assets (b) 		Fair Value of
Financial Liabilities
2 % $ 468  $ 245  $ (3,116) $ (7,467)
1 234  122  (1,576) (4,059)
(1) (80) (14) 1,226  4,741 
(2) (80) (14) 1,689  9,821 
Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of March 31, 2021, the assumed hypothetical change in interest rates does not reflect the full 100 and 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero. As of March 31, 2021 and 2020, some of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does not reflect the full 200 basis point reduction.
22
ITEM 4.    CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2021. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2021.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.    LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 6 of Notes to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.
ITEM 1A.    RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2020 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2020 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2020 10-K.
ITEM 2.    UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates periodically. There is no established expiration date for the program. During the first quarter 2021, we repurchased approximately 5 million shares at an average price of $345.42 per share. As of March 31, 2021, we had Board authorization to purchase up to 53 million shares of our common stock.
23
ITEM 6.    EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1
3.2
4.1
4.2
4.3
4.4
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104  Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
 ________________
* Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
24
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
UNITEDHEALTH GROUP INCORPORATED
 
/s/ ANDREW P. WITTY
Chief Executive Officer
(principal executive officer) 		Dated: May 5, 2021
Andrew P. Witty   
/s/ JOHN F. REX
Executive Vice President and
Chief Financial Officer
(principal financial officer) 		Dated: May 5, 2021
John F. Rex   
/s/ THOMAS E. ROOS
Senior Vice President and
Chief Accounting Officer
(principal accounting officer) 		Dated: May 5, 2021
Thomas E. Roos   
25
UnitedHealth (NYSE:UNH)
過去 株価チャート
から 3 2024 まで 4 2024 UnitedHealthのチャートをもっと見るにはこちらをクリック
UnitedHealth (NYSE:UNH)
過去 株価チャート
から 4 2023 まで 4 2024 UnitedHealthのチャートをもっと見るにはこちらをクリック